PubMed Health⌕ Search

Biomedical subjects

M Crivellaro

Publications and source records attributed to M Crivellaro.

20 records · Page 2Linked to original sources

[New drugs in the treatment of respiratory allergic diseases].

The drugs recently available for the treatment of allergic respiratory diseases include: 1) topical steroids as fluticasone and budesonide; 2) nasal and ocular sodium nedocromil; 3) nasal N-acetyl-aspartyl-glutamic acid; 4) topical antihistamines as levocabastine and azelastine; 5) antileukotrienes and anti PAF (experimental). Topical steroids are the most effective drugs; the new molecules have a low gastric absorption and a rapid liver-metabolism which decreases the risks of systemic side effects. In the treatment of allergic conjunctivitis ocular sodium nedocromil seems to be more effective than cromoglycate, however further studies are needed to evaluate the effectiveness of the nedocromil nasal formulation. In allergic rhinitis good clinical results are obtained using NAAGA. In the treatment of allergic rhino-conjunctivitis topical antihistamines seem as effective as the antihistamines administered by oral route; moreover they cause less side effects. The anti-leukotrienes drugs can be used in the treatment of moderate asthma. In the treatment of bronchial asthma no clinical and functional improvement has been reported using PAF or thromboxane A2 receptor antagonists.

Administration, Topical↗

The relationship between clinical efficacy of specific immunotherapy and serum intercellular adhesion molecule-1 levels.

The intracellular adhesion molecule-1 (ICAM-1) is a reliable marker of allergic inflammation; its soluble isoform in serum is hypothesized to reflect the severity of the disease, therefore it may be used to monitor the efficacy of specific immunotherapy. We evaluated the levels of soluble ICAM-1 in the serum of 14 patients with grass-induced respiratory allergy before and after 12 months of specific immunotherapy, and correlated this parameter with the clinical outcome, measured using a visual analog scale. We found that in the majority of the patients, soluble ICAM-1 levels paralleled the clinical trend of the disease, with a significant decrease of soluble ICAM-1 in patients with successful specific immunotherapy (Spearman's correlation test: r = 0.57; p < 0.001). Therefore, we hypothesize that soluble ICAM-1 could be regarded as a reliable indirect marker of specific immunotherapy efficacy and that it could be used for monitoring clinical outcome.

Adolescent↗